| Autor: |
Babinska, A, Markell, M S, Salifu, M O, Akoad, M, Ehrlich, Y H, Kornecki, E |
| Zdroj: |
Nephrology Dialysis Transplantation; December 1998, Vol. 13 Issue: 12 p3153-3159, 7p |
| Abstrakt: |
Rapamycin is a new immunosuppressive drug of the macrolide type. Despite binding to one of the FK-binding proteins as the initial step in intracellular action, further effects differ from those of the other fungally derived macrolides, cyclosporine and tacrolimus. We have previously demonstrated an enhancement of agonist-mediated platelet activation by cyclosporine and tacrolimus which was associated with increased phosphorylation of two intracellular platelet proteins, p20 and p40. Because rapamycin utilizes the same class of binding proteins as tacrolimus, but its action is not associated with the inhibition of calcineurin, we postulated that if the stimulatory effect of cyclosporine or tacrolimus was due to calcineurin inhibition, rapamycin should not affect platelets in a similar fashion. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
